PipelineQurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.
| Discovery | Candidate | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |||
|---|---|---|---|---|---|---|---|---|
| Oncology | Adrixetinib (Q702) Axl/Mer/CSF1R Inhibitor |
Solid Tumors Mono |
||||||
| Pembrolizumab Combo |  |
|||||||
| Hematologic Malignancies | ||||||||
| Mocaciclib (Q901) selective CDK7 inhibitor |
Solid Tumor Mono/Combo |
|||||||
| Pembrolizumab Combo | |
|||||||
| Proteasome inhibitor ADC | Cancer/ Autoimmune Disease |
 |
||||||
| Anti Inflammation |
(Q301) Topical 5LO Inhibitor |
Atopic Dermatitis |
||||||
| Anti infective |
Telacebec, (Q203) Cyt bc1 Inhibitor |
Mycobacterial Infections Tuberculosis/ Non-TBM |
 |
|||||
| Candidate | Pre-Clinical | Phase 1 | Phase 2 | ||
|---|---|---|---|---|---|
| Adrixetinib (Q702) Axl/Mer/CSF1R Inhibitor |
Solid Tumors Mono |
||||
| Pembrolizumab Combo |
|
||||
| Hematologic Malignancies |
|||||
| Mocaciclib (Q901) Selective CDK7 Inhibitor |
Solid Tumor Mono/Combo |
||||
| Pembrolizumab Combo |
|
||||
| Proteasome inhibitor ADC | Cancer/ Autoimmune Disease |
||||
| Q301 Topical 5LO Inhibitor |
Atopic Dermatitis |
||||
| Telacebec (Q203) Cyt bc1 Inhibitor |
Mycobacterial Infections Tuberculosis/ Non-TBM |
|
|||